A summary of current health news details EU regulators probing Novo Nordisk's $16.5 billion Catalent takeover, Amgen's ...

A European Union court upheld the bloc's decision to approve Vodafone's acquisition of some of Liberty Global's telecommunications assets, thwarting a legal challenge from German telecom rivals.

AstraZeneca has announced $3.5bn in capital investment aimed at expanding its US research and manufacturing capabilities by ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

Consumers started their Christmas shopping early, Kantar says; UK jobless rate rises to 4.3% while wage growth excluding ...

EU mid-market update: Trump trade train in full steam ahead mode; Germany dials in election for Feb 23rd, while its ZEW index ...

Tezspire is currently approved for the treatment of severe asthma in the US, EU, Japan, and nearly 60 countries across the globe. It is approved as a single-use pre-filled syringe and auto-injector ...

AstraZeneca raises its fiscal 2024 guidance for the second consecutive quarter. This upgrade comes despite ongoing legal ...

TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo ...

(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

At the 2024 EU-TW 6G SNS Joint Workshop in Taipei, the Industrial Technology Research Institute (ITRI), alongside its ...